The resulting compound has reported serum half-life and blood-brain-barrier permeability sufficient for oral and intragastric administration in rodent studies, which is unusual for a peptide derivative of this size
Clinical research and evidence Epitalon has been studied for over 35 years, primarily in Russia, with some remarkable findings: A 12-year study on elderly patients showed a 28% lower mortality rate in the Epitalon group compared to controls Research demonstrated restoration of melatonin production in aging monkeys Studies showed improved immune function and T-cell counts in elderly subjects Laboratory research confirmed telomerase activation and telomere lengthening in human cells While more widespread clinical trials are needed, the existing research provides compelling evidence for Epitalons potential in addressing fundamental aspects of aging
doi:10.1016/j.ctim.2019.102201
FOXO4-DRI is primarily investigated in cellular aging, senescence biology, and longevity-related research contexts
Oral administration (capsule or lozenge) is more convenient and may be appropriate when the primary goal is GI support, since BPC-157 is remarkably stable in gastric juice
This medicine also increases stomach muscle contraction and may improve gastric emptying
